ライフサイエンスコーパス: in-hospital

1 , 282 (24.5%) died, and 831 (72.2%) remained in hospital.

2 10 698 (11.1%) patients died in hospital.

3 ng surgery requiring at least a 1-night stay in hospital.

4 ross 613 U.S. hospitals, 12,388 (18.6%) died in-hospital.

5 of the most commonly prescribed antibiotics in hospitals.

6 ch to maintain the cleanliness of indoor air in hospitals.

7 ially regarding coverage and quality of care in hospitals.

8 the adaptation process of external AI models in hospitals.

9 involved in the transmission of A. baumannii in hospitals.

10 The TAVR group had similar in-hospital (1.8% vs. 2.0%) and 30-day mortality (3.6% v

11 likely to die in the ICU (12.3% vs 7.5%) and in-hospital (20.8% vs 13.5%) (p < 0.0001).

12 In-hospital, 30-day, and 90-day mortality were 3.2%, 3.6

13 In-hospital, 6-month and 12-month mortality were studied

14 e frequently satisfied with support received in hospital (95%) compared to primary care (76%) or comm

15 ital but were not at increased risk of dying in-hospital (adjusted odds ratio, 1.03; 0.98-1.07).

16 0.15% to 0.27%; adjusted P < 0.001) increase in hospital admissions for diseases of the digestive sys

17 8.0 episodes) of clinical pneumonia resulted in hospital admissions of older adults worldwide.

18 atient population, performing hospitals, and in-hospital adverse event rates.

19 ropean prospective snapshot study found a 5% in-hospital after TP.

20 ve been infected and outbreaks have occurred in hospitals, aged care facilities and prisons.

21 hospitalized for COVID-19 are predictive of in-hospital AKI and the need for dialysis.

22 ic regression analysis to assess the risk of in-hospital AKI occurrence based on admission serum ioni

23 ized calcium and in-hospital AKI, with nadir in-hospital AKI was in serum ionized calcium of 5.00-5.1

24 between admission serum ionized calcium and in-hospital AKI, with nadir in-hospital AKI was in serum

25 ssociation between suPAR levels and incident in-hospital AKI.

26 ensive care unit, mechanical ventilation, or in-hospital all-cause mortality) was comparable between

27 Stepwise decreases in hospital and 1-year mortality were observed with high

28 , and handheld computer devices for 6 months in hospital and at home.

29 hat express efflux transporters such as NorC in hospital and community settings.

30 racterizing antibiotic resistance reservoirs in hospitals and establish the feasibility of systematic

31 are increased risks of contracting COVID-19 in hospitals and long-term care facilities, particularly

32 he end-of-life experience for patients dying in hospitals and their families.Objectives: We measured

33 his retrospective cohort of ACS, BB improved in-hospital and 1-month mortality in patients with a LVE

34 No differences in in-hospital and 1-year mortality were found, whereas rel

35 re performed to investigate risk factors for in-hospital and 1-year mortality, as well as relapses.

36 isk of paravalvular regurgitation and higher in-hospital and 2-year mortality compared with use of BE

37 component, 30-day readmission, and all-cause in-hospital and 30-day mortality.

38 ated with a poor prognosis, with a very high in-hospital and late death rate.

39 metapneumovirus-associated ALRI deaths (both in-hospital and non-hospital deaths).

40 the 10-year period; 428 (79%) patients died in hospital, and 456 (84%) died 6 months after injury.

41 he changes in safe patient handling programs in hospitals, and nurses' perceptions, work practices, a

42 95% CI 1.27-1.31), and number of days spent in hospital as an inpatient (1.38, 1.35-1.41).

43 ular complication while 7.6% (n=2651) had an in-hospital bleeding event.

44 ithout AKI, including a higher proportion of in-hospital bleeding events (3.8% vs. 0.8%; p = 0.011),

45 cement in the US, vascular complications and in-hospital bleeding events were common, but rates have

46 ing rapid response team review stayed longer in hospital but were not at increased risk of dying in-h

47 The prevalence of malnutrition remains high in hospitals but no "gold standard" has been established

48 ndirect transmission from patient to patient in hospitals can drive infections, supported by this org

49 Limitations in hospital capacity may result in difficult decisions i

50 gency treatments like resuscitation care for in-hospital cardiac arrest (IHCA).

51 erence to process measures or outcomes after in-hospital cardiac arrest (IHCA).

52 Germane to in-hospital cardiac arrest are recommendations about the

53 e sites may provide opportunities to improve in-hospital cardiac arrest care at other hospitals.

54 used data from 84 089 adult patients with an in-hospital cardiac arrest from 166 hospitals with conti

55 s risk-standardized survival rate (RSSR) for in-hospital cardiac arrest has emerged as an important m

56 All children received standard in-hospital care for severe anemia and a 3-day course of

57 plementation and mechanical ventilation, and in-hospital case fatality (hCFR) among children with BPD

58 We estimated the hospital admission rate and in-hospital case-fatality ratio (CFR) of pneumonia in ol

59 mmunity incidence, hospitalization rate, and in-hospital case-fatality ratio (hCFR) of RSV-ARI in old

60 ted incidence, hospital admission rates, and in-hospital case-fatality ratios (hCFRs) of human metapn

61 of in-hospital pneumonia deaths by combining in-hospital CFRs with hospital admission estimates from

62 rience of cases of refractory anaphylaxis at in-hospital challenge and propose a framework for escala

63 revascularization was associated with better in-hospital clinical outcomes compared with surgical rev

64 ccounting for different coding practices for in-hospital comorbidities.

65 adjusted for preexisting conditions but not in-hospital comorbidity measures were not significantly

66 9] open; P<0.001), driven by a lower rate of in-hospital complications (6.6% EVR versus 38.0% open; P

67 In-hospital complications are uncommon and rarely life-t

68 Presenting symptoms and in-hospital complications were similar between the cance

69 ost-operative analgesia, major reductions in in-hospital consumption of opioids, and reduced pain, co

70 was not associated with significant changes in hospital costs in patients hospitalized with sepsis i

71 In hospitals, CT is typically used to image the neurocra

72 obesity was associated with a higher risk of in-hospital death (hazard ratio, 1.26 [95% CI, 1.00-1.58

73 ze (i.e., body mass index) is a predictor of in-hospital death among all-comers with sepsis-providing

74 cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with Covid

75 ease is associated with an increased risk of in-hospital death among patients hospitalized with Covid

76 was associated with higher adjusted risk of in-hospital death and major bleeding complications, alth

77 ed survival analysis with primary outcome of in-hospital death associated with myocardial injury.

78 ion models were used to estimate the odds of in-hospital death by body mass index category; two-way i

79 $64,400) for those with an estimated risk of in-hospital death exceeding 15% (based on the Simplified

80 anical ventilation occurred in 2109 (27.7%), in-hospital death in 1302 (17.1%), and mechanical ventil

81 The primary outcome was in-hospital death in a time-to-event analysis assessed a

82 o ascertain the extent of risk reduction for in-hospital death in COVID-19.

83 as an independent risk factor for all-cause in-hospital death in patients with COVID-19.

84 2)) was associated with an increased risk of in-hospital death only in those <=50 years (hazard ratio

85 obesity were associated with higher risks of in-hospital death or mechanical ventilation (odds ratio,

86 Among 7606 patients, in-hospital death or mechanical ventilation occurred in

87 ndently associated with an increased risk of in-hospital death were an age greater than 65 years (mor

88 Other clinical variables (in-hospital death, hospital length of stay, intensive ca

89 In-hospital death, thromboembolism, mechanical ventilati

90 ctive effect of RAASi with a reduced risk of in-hospital death.

91 The primary outcome was the rate of in-hospital death.

92 ical ventilation, or vasopressor therapy) or in-hospital death.

93 000), 7700 human metapneumovirus-associated in-hospital deaths (2600 to 48 800), and 16 100 overall

94 rtality, we estimated that about 1.1 million in-hospital deaths (UR, 0.9-1.4 in-hospital deaths) occu

95 imated human metapneumovirus-associated ALRI in-hospital deaths and overall human metapneumovirus-ass

96 mates of the burden of first recurrences and in-hospital deaths did not change significantly.

97 We estimated the number of in-hospital deaths due to RSV-ARI by combining hCFR data

98 were in infants under 12 months, and 64% of in-hospital deaths occurred in infants younger than 6 mo

99 3% of the hospital admissions and 36% of the in-hospital deaths were in infants under 6 months.

100 1.1 million in-hospital deaths (UR, 0.9-1.4 in-hospital deaths) occurred among older adults.

101 ssociated ALRI deaths based on the number of in-hospital deaths, US paediatric influenza-associated d

102 fted to urgent appendectomy, with acceptable in-hospital delays of up to 24 hours.

103 The median time to in-hospital deterioration was 3 days (IQR 1-6).

104 eases, 10th Edition, coding strategy for use in hospital discharge data.

105 uinine and artesunate either in mortality or in hospital discharge rate, with hazard ratios (HRs) of

106 ifference was found in terms of mortality or in hospital discharge rates between artesunate- and quin

107 ors present on admission, a model to predict in-hospital disease progression had an area under the cu

108 ely, the first X-ray machines were installed in hospitals during this period, and the first installat

109 Patients who underwent surgical procedures in hospitals experiencing major decreases in LOS were de

110 (37% versus 27%, p = 0.002) and AD inclusion in hospital files (10% versus 3%, p < 0.001) were more l

111 specialist palliative care and AD inclusion in hospital files of intervention patients is meaningful

112 Although very rare, fatal anaphylaxis during in-hospital food challenge has been reported.

113 face sterility validation, which is critical in hospitals, food and pharmaceutical industries to help

114 iation between gestational age and mortality in hospital for term-born neonates (>= 37 wk') admitted

115 tes indicated that such microbes can persist in hospitals for extended periods (>8 years), to opportu

116 der adults with RSV-ARI in the community and in hospitals for that year.

117 tered nurses and nursing assistants) working in hospitals have been adopted widely.

118 There were four trial sites in hospitals in Ghana (Agogo, Tepa, Nkawie, Dunkwa) and

119 While implementation of CCRTs in hospitals in Ontario, Canada, did not reduce FTR amon

120 In people, omeprazole is overprescribed in hospitals, increasing the risk of adverse effects and

121 Patients were randomly assigned 1:1 to in-hospital initiation of S/V (n = 440) versus enalapril

122 ed From an Acute Heart Failure Episode), the in-hospital initiation of sacubitril/valsartan in patien

123 red in routine practice, suggesting that the in-hospital initiation of sacubitril/valsartan should be

124 s ratio, 0.39 [95% CI, 0.24-0.67]; P<0.001), in-hospital major adverse cardiac and cerebral events (o

125 The primary outcome measure was in-hospital major adverse cardiac events defined as a co

126 mary outcomes were in-hospital mortality and in-hospital major bleeding.

127 syndrome in England and to evaluate whether in-hospital management of patients has been affected as

128 Early risk stratification is essential for in-hospital management of ST-segment-elevation myocardia

129 Older people's care experiences in hospital may be negative in the absence of relational

130 c AKI-RRT patients had longer length of stay in hospital [median (IQR):15 (5-34) days vs. 6 (3-11) da

131 isk, 1.90 [95% CI, 1.63-2.22]; P<0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk,

132 rs vs histamine-2 receptor blockers resulted in hospital mortality rates of 18.3% vs 17.5%, respectiv

133 There was no significant difference in hospital mortality.

134 ificant difference between groups, including in-hospital mortality (1.7% for uncemented fixation vs 2

135 mitted during influenza season had increased in-hospital mortality (11.0% vs. 5.8%, p = 0.024) and in

136 Neither total in-hospital mortality (13/46 [28%] versus 22/104 [21%];

137 (7.9% versus 8.6%, P=0.12), no difference in in-hospital mortality (2.2% versus 2.2% P=0.99), and a g

138 Female sex was an independent predictor of in-hospital mortality (23.0% versus 21.7%; adjusted odds

139 rsus 22/104 [21%]; P = 0.3) nor attributable in-hospital mortality (9/46 [20%] versus 13/104 [12%]; P

140 n = 1,959; 44.6%) were associated with lower in-hospital mortality (adjusted hazard ratio [aHR]: 0.53

141 Higher LVSWI was associated with lower in-hospital mortality (adjusted odds ratio, 0.72 per 10

142 ulation-associated major bleeding had higher in-hospital mortality (adjusted odds ratio, 1.49; 95% CI

143 ise-comparisons <0.001) and increase in TAVR in-hospital mortality (adjusted OR, 6.13 [95% CI, 1.97-1

144 y use, stimulant-only use had higher risk of in-hospital mortality (aRR 1.26, 95% CI 1.03-1.46).

145 ion odds ratio, 0.36; 95% CI, 0.32-0.40) and in-hospital mortality (odds ratio, 0.48; 95% CI 0.40-0.5

146 rritin levels were associated with increased in-hospital mortality (odds ratio, 1.518 per log ug/L [9

147 ratio on day 1 were associated with a higher in-hospital mortality (odds ratios, 1.19 and 1.17, respe

148 .11-3.23) while older age was a predictor of in-hospital mortality (OR 4.18; 95% CI 1.94-9.04).

149 between the proposed SCAI staging system and in-hospital mortality among patient with heart failure a

150 need for invasive mechanical ventilation and in-hospital mortality among patients admitted with asthm

151 monary and noncardiopulmonary complications, in-hospital mortality and 30-day readmission for HFrEF c

152 endpoints included length of hospital stay, in-hospital mortality and adverse events.

153 The primary outcomes were in-hospital mortality and in-hospital major bleeding.

154 y hemorrhage may have the greatest impact on in-hospital mortality and organ failure.

155 The main outcomes of interest were in-hospital mortality and the occurrence of de-novo vent

156 n of increasing severity of hyponatremia and in-hospital mortality assessed using multivariable logis

157 was to describe contemporary management and in-hospital mortality associated with blunt thoracic aor

158 aracterize COVID-19-associated morbidity and in-hospital mortality by race/ethnicity.

159 valve surgery on rates of valve surgery and in-hospital mortality for endocarditis is not known.

160 s, regardless of IDU status, and a reduction in-hospital mortality for patients with IE.

161 ed relationships between these variables and in-hospital mortality in a log-binomial model.

162 ) of IFN-alpha2b was associated with reduced in-hospital mortality in comparison with no admission of

163 hyperglycemia ratio, independently predicts in-hospital mortality in critically ill patients across

164 erpretable, and highly accurate predictor of in-hospital mortality in elderly ES patients up to age 8

165 Several factors predict in-hospital mortality in fibrotic interstitial lung dise

166 pectively, the patients per nurse ratio with in-hospital mortality in ICUs.

167 dictive performance of prognostic scores for in-hospital mortality in patients with aSAH.

168 intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons o

169 found between patients per nurse ratios and in-hospital mortality in The Netherlands.

170 mechanical ventilation-related predictors of in-hospital mortality included achieving early targeted

171 Unadjusted clinical predictors of in-hospital mortality included age (unit odds ratio, 1.0

172 In-hospital mortality occurred in 95 patients (3.6%), or

173 e volume and examined in relation to average in-hospital mortality of the highest volume quintile.

174 ly more likely to have a combined outcome of in-hospital mortality or discharge to hospice (25.9% ver

175 Outcomes were assessed as in-hospital mortality or recovery.

176 The overall in-hospital mortality rate was 59.9%.

177 assess for changes in valve replacement and in-hospital mortality rates after the public reporting i

178 f this study was to examine whether elevated in-hospital mortality rates in lower volume hospitals ar

179 Importantly, in-hospital mortality rates were almost 385-fold higher

180 atient specific risk factors or only predict in-hospital mortality rates.

181 ctivities Score per nurse ratio on day 1 and in-hospital mortality remained significant (odds ratios,

182 an approach to identify patients at risk for in-hospital mortality remains under investigation.

183 peratively and IT does not confer additional in-hospital mortality risk.

184 ated less aggressively and experience higher in-hospital mortality than men.

185 eristic curve of the LUCK classification for in-hospital mortality was 0.89 (P=0.001), and of the Kil

186 ; 33% developed sepsis, 6% septic shock, and in-hospital mortality was 14%.

187 For the full cohort of patients, in-hospital mortality was 19.0%, and the median intensiv

188 Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%).

189 In-hospital mortality was 30% for venovenous extracorpor

190 In-hospital mortality was 31% for the total cohort, but

191 In-hospital mortality was 35.0% with a high viral load (

192 In-hospital mortality was 5% and 90-day mortality 8%.

193 In-hospital mortality was 50% among patients with AKI ve

194 Overall in-hospital mortality was 56%, but rates were higher whe

195 In-hospital mortality was 8.8% for the entire patient co

196 Although in-hospital mortality was 9%, 35% of survivors demonstra

197 All-cause 30-day in-hospital mortality was 958 (4.0%) in Improving Pediat

198 ursing Activities Score per nurse ratio with in-hospital mortality was analyzed using logistic regres

199 Risk for in-hospital mortality was associated with increasing SCA

200 In regression analysis, in-hospital mortality was associated with longer CPB tim

201 In-hospital mortality was evaluated for association with

202 In the subgroup analysis, in-hospital mortality was lower in patients operated in

203 Compared with the Northeast, in-hospital mortality was lower in the Midwest (adjusted

204 tween clinical risk factors, biomarkers, and in-hospital mortality was modelled using Cox proportiona

205 In-hospital mortality was not associated with the use of

206 qSOFA >= 2 and maximum qSOFA >= 2 to predict in-hospital mortality were 33% and 69%, respectively.

207 Adjusted odds of in-hospital mortality were 39% greater in patients who m

208 Rates of in-hospital mortality were 5.2%, 18.6%, and 31.7% in pat

209 Predictors for major complications and in-hospital mortality were assessed in multivariable log

210 Age-standardized rates of operations and in-hospital mortality were calculated and mapped.

211 al length of stay (HLOS); complications; and in-hospital mortality were compared before (PRE) and aft

212 gic)/transient ischemic attack incidence and in-hospital mortality were extracted.

213 , variables that were associated with higher in-hospital mortality were increasing age and presentati

214 ification improved Killip ability to predict in-hospital mortality with a net reclassification improv

215 rt, lab, and output events for prediction of in-hospital mortality without variable selection.

216 nsive care unit, mechanical ventilation, and in-hospital mortality) were captured from electronic hea

217 univariable and multivariable predictors of in-hospital mortality, adjusted for confounding with an

218 relevant hospitalization outcomes, including in-hospital mortality, after controlling for key demogra

219 ts were largely insensitive to variations in in-hospital mortality, age at baseline, or costs of reho

220 regression was used to compare the odds for in-hospital mortality, and the average marginal effects

221 19 patients, was an independent predictor of in-hospital mortality, and was associated with increased

222 pella use, and associated clinical outcomes (in-hospital mortality, bleeding requiring transfusion, a

223 and diabetes, no significant differences in in-hospital mortality, ICU admission, or mechanical vent

224 ry endpoints were antimicrobial consumption, in-hospital mortality, length of stay (LOS), and the inc

225 Secondary outcomes included an evaluation of in-hospital mortality, length of stay, infusion-related

226 Outcomes were in-hospital mortality, mortality rates based on insuranc

227 ome was AKI, and secondary outcomes included in-hospital mortality, need for ventilatory support, int

228 occurrence of paravalvular regurgitation or in-hospital mortality, or both.

229 neumonia) with each unfavorable outcome [ie, in-hospital mortality, organ failure, prolonged hospital

230 rt, the primary end point was a composite of in-hospital mortality, renal replacement therapy, or sev

231 1.31-1.47) and 4.32 (95% CI, 4.06-4.59) for in-hospital mortality, respectively.

232 Outcomes of interest included in-hospital mortality, use of cardiac interventions, hos

233 End points of interest included in-hospital mortality, use of coronary angiography, perc

234 The primary outcome, in-hospital mortality, was analyzed using a multivariabl

235 age, and comorbidities contributed to higher in-hospital mortality, while distal perfusion cannula wa

236 itals suffered significantly higher rates of in-hospital mortality.

237 ndently associated with an increased risk of in-hospital mortality.

238 cal ventilation or patients who evolved with in-hospital mortality.

239 hanical ventilation strategies might improve in-hospital mortality.

240 e per nurse ratio was associated with higher in-hospital mortality.

241 th delirium duration, delirium severity, and in-hospital mortality.

242 length of stay, hospital length of stay, and in-hospital mortality.

243 ceipt of invasive mechanical ventilation and in-hospital mortality.

244 actor-1 were not found to be associated with in-hospital mortality.

245 ses ED dwell times, complications, HLOS, and in-hospital mortality.

246 access to TAVR, TAVR utilization rates, and in-hospital mortality.

247 ently associated with risk of intubation and in-hospital mortality.

248 examination to identify patients at risk for in-hospital mortality.

249 (aOR, 4.86 [1.92-12.28]) had higher rates of in-hospital mortality.

250 pulmonary organ dysfunction, and substantial in-hospital mortality.

251 e incidences of PPCI, delayed treatment, and in-hospital mortality.

252 g and approach of thoracic aortic repair and in-hospital mortality.

253 ents per nurse ratio was not associated with in-hospital mortality.

254 hospital lengths of stay, complications, and in-hospital mortality.

255 nt and hospital factors were associated with in-hospital mortality.

256 copically incomplete resection, or 3) 30-day/in-hospital mortality.

257 quartile 4 were also associated with higher in-hospital mortality.

258 harge (PDD, or "against medical advice") and in-hospital mortality.

259 linical cure, acute kidney injury (AKI), and in-hospital mortality.

260 period for ED-LOS, HLOS, complications, and in-hospital mortality.

261 difference, 16.1 d; 95% CI, 8.4-23.7) or die in hospital (odds ratio, 4.6; 95% CI, 1.8-11.8) than tho

262 (odds ratio, 4.4; 95% CI, 3.0-6.4), and die in hospital (odds ratio, 6.4; 95% CI, 2.8-14.0) (p < 0.0

263 regulations of the medical ethics committee in Hospital of Stomatology, Hebei Medical University app

264 gression models were used to compare changes in hospital-onset multidrug-resistant organism bloodstre

265 Differences regarding in-hospital opioid consumption, discharge prescribing of

266 Of these 647, 116 (17.9%) either died in hospital or were discharged to hospice and were exclu

267 or nursing students or professionals working in hospitals or community settings, and all but one stud

268 ids available over the counter or prescribed in hospitals or drug treatment centres.

269 study was to examine association of AC with in-hospital outcomes and describe thromboembolic finding

270 ine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19.

271 ical presentation, treatment strategies, and in-hospital outcomes of patients undergoing percutaneous

272 For comparison of in-hospital outcomes, propensity-score matching was empl

273 tal admission, clinical characteristics, and in-hospital outcomes.

274 In-hospital pediatric sepsis mortality has decreased sub

275 -of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group; n

276 345), and out-of-hospital placebo bolus and in-hospital placebo 8-hour infusion (placebo group; n =

277 We estimated the number of in-hospital pneumonia deaths by combining in-hospital CF

278 Secondary outcomes were mortality (in-hospital, postdischarge, and overall), 90-day medical

279 Researching Effective Approaches to Cleaning in Hospitals (REACH) study implemented an environmental

280 ivities were beneficial for identifying gaps in hospital readiness.

281 cological interventions for refusals of care in hospital settings and in community settings with home

282 uded 116 studies, of which 50 were conducted in hospital settings, 24 were delivered in community set

283 (AKI), a complication that frequently occurs in hospital settings, is often associated with hemodynam

284 in positive group; P = .004), and a shorter in-hospital stay (34 days [IQR 18-55] vs 51 days [IQR 35

285 Adjusted in-hospital survival (odds ratio, 0.39 [95% CI, 0.24-0.6

286 score mean+/-SD, -8.9+/-4.4) predicting 30% in-hospital survival; ventilation 94%, dialysis 56%.

287 e period, the RR was 0.85 (95% CI 0.80-0.91) in hospitals that did not implement CCRT.

288 Among patients in hospitals that introduced CCRT, the relative risk (RR

289 ontact precautions were discontinued but not in hospitals that maintained contact precautions.

290 -of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus

291 nd multiple imputation to adjust for changes in hospital usage and missing data.

292 predictions and yielded substantial movement in hospitals' utilization rankings.

293 The primary outcomes were in-hospital vascular complications and bleeding events.

294 terquartile range, 38.2-40 wk) and mortality in hospital was 6.6%.

295 The establishment of early warning systems in hospitals was strongly recommended in recent guidelin

296 ssociated rise in VRE bloodstream infections in hospitals where contact precautions were discontinued

297 After hip fracture repair, patients in hospitals with major decreases in LOS had a higher ri

298 younger with fewer comorbidities than those in hospitals with no defined pathway but with similar pr

299 prescriptions were inappropriate, especially in hospitals without a strategy to manage fluoroquinolon

300 ion, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials f